HDAC9 and uveal melanoma: Recent trials of widespread metastatic uveal melanoma such as PEMDAC trial investigated the use of pembrolizumab (PD1 inhibitor) and entinostat a class 1 HDAC inhibitor shown to promote immune checkpoint inhibition [83].